Business Context and Reporting Period
This Form 8-K Current Report was filed by Compass Therapeutics, Inc. on December 21, 2021, covering the event date of December 20, 2021. The filing addresses corporate governance changes rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 regarding officer departures and does not contain financial statements.
Material Changes
The material change reported is the resignation of Julie Sunderland from the Board of Directors and all associated committees, effective December 31, 2021. The Company stated that the resignation was not the result of any disagreement regarding operations, policies, or practices. Ms. Sunderland, an early venture investor, is departing to pursue other professional endeavors.
Guidance, Outlook, and Risks
The filing contains no management commentary on financial guidance, future outlook, or specific risk factors. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Confirm the effective date of Julie Sunderland's resignation (December 31, 2021).
- Verify if the Board has announced a replacement director to fill the vacancy.
- Review the Company's most recent 10-K or 10-Q for current financial health, as this 8-K contains no financial data.